Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Melbourne University and Bio Farma to Jointly Develop Vaccine Adjuvant

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Agreement to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases.

Melbourne University has announced an agreement with Indonesian vaccine maker Bio Farma to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases, including Hepatitis C, Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemopilus influenza type-B.

"Bio Farma is proud to collaborate with the University of Melbourne. This agreement will surely give us an opportunity to enhance our research capacity," said Iskandar, the President Director of Bio Farma.

Iskandar expressed hope in the future of the collaboration on a vaccine delivery system to boost vaccine effectiveness (vaccine adjuvant) which would lead into a real contribution in the prevention of communicable disease in the world.

Under the proposed arrangement, Melbourne University receives research funding to further evaluate and develop a proof of concept.

The research agreement was facilitated by UoM Commercial Ltd, the University's Commercial Engagement Service company and signed on 3 September 2012.

According to Iskandar, the collaboration with Melbourne University will run for 18 months as presently the research is still in the level of proof of concept.

Upon getting a result, the next step will be enhanced to a technology license level.

Professor James Angus, Dean of the Faculty of Medicine, Dentistry and Health Sciences at Melbourne University, remarked that he was delighted to be collaborating with the Board of Bio Farma and its scientific team in relation to developing a novel vaccine platform.

The vaccine platform would lead to better and more efficacious vaccines against infectious diseases. "This agreement reflects the desire for research at the University of Melbourne to be translated into impact and recognizes the importance of collaboration with leading vaccine companies to achieve this goal," said Professor Angus.

Research led by Professor David Jackson's team in the Department of Microbiology and Immunology at the University of Melbourne has shown that a synthetic TLR2 agonist-based adjuvant can enhance immunity and protect animals from viral and bacterial infections.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Scientists Are a Step Closer to Treating Toxoplasmosis
Researchers are a step closer to developing drug targets for Toxoplasmosis, after gaining insight into its unique feeding behaviour.
Friday, August 14, 2015
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Thursday, August 06, 2015
U of Melbourne Launches Genomics Research Center for Infectious Disease
The Peter Doherty Institute for Infection and Immunity has launched the Doherty Centre for Applied Microbial Genomics, which is set to help transform the detection, tracking and treatment of infectious diseases in Australia.
Thursday, July 23, 2015
‘Atomic Chicken-Wire’ Is Key To Faster DNA Sequencing
An unusual and very exciting form of carbon - that can be created by drawing on paper- looks to hold the key to real-time, high throughput DNA sequencing, a technique that would revolutionise medical research and testing.
Monday, March 30, 2015
Typhoid Gene Unravelled
Natural resistance against typhoid fever is linked to a particular form of the HLA-DRB1 gene.
Tuesday, November 11, 2014
Blood Test Developed to Diagnose Early Onset Alzheimer’s Disease
New blood-test could predict a person’s risk of developing AD much earlier than is currently possible.
Thursday, October 30, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!